Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
South Korea · Delayed Price · Currency is KRW 6,100.00
-70.00 (-1.13%)
At close: Apr 9, 2026
Seoulin Bioscience Revenue
In the year 2025, Seoulin Bioscience had annual revenue of 77.09B KRW with 2.23% growth. Seoulin Bioscience had revenue of 19.96B in the quarter ending December 31, 2025, with 1.80% growth.
Revenue
77.09B
Revenue Growth
+2.23%
P/S Ratio
0.70
Revenue / Employee
741.26M
Employees
104
Market Cap
53.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 77.09B | 1.68B | 2.23% |
| Dec 31, 2024 | 75.41B | -14.16B | -15.81% |
| Dec 31, 2023 | 89.57B | -15.14B | -14.46% |
| Dec 31, 2022 | 104.71B | 24.17B | 30.01% |
| Dec 31, 2021 | 80.54B | 15.45B | 23.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Medical Science | 108.41B |
| Dx & Vx | 29.36B |
| Cytogen | 26.05B |
| Protia | 15.12B |
| HLB Panagene | 15.05B |
| 3billion | 11.71B |
| GENINUS | 10.48B |
| Median Diagnostics | 7.86B |